239MO - Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials

Background

The relationships between body mass index (BMI) and survival outcomes are complex, and have not been thoroughly investigated in breast cancer patients who received adjuvant chemotherapy.

Methods

We collected data on 2394 patients from two randomized, phase III clinical trials that investigated adjuvant chemotherapy in breast cancer identified in Project Data Sphere. The objective was to examine the effect of baseline BMI, BMI after adjuvant chemotherapy, and BMI change from baseline to post-adjuvant chemotherapy on disease-free survival (DFS) and overall survival (OS). Restricted cubic splines, adjusting for confounding factors, were used to examine potential non-linear associations between continuous BMI value and survival. Stratified analyses involved chemotherapy regimens used.

Results

On multivariate analysis, severe obesity (BMI≥40.0 kg/m²) at baseline was independently associated with worse DFS (HR=1.48, 95%CI 1.02-2.16, P=0.04) and OS (HR=1.79, 95%CI 1.17-2.74, P=0.007) compared with underweight/normal weight (BMI≤24.9 kg/m²). A BMI loss >10% was also an independent prognostic factor for adverse OS (HR=2.14, 95%CI 1.17-3.93, P=0.014). When stratified by chemotherapy regimens, the multivariate analysis revealed that severe obesity adversely affected DFS (HR=2.38, 95%CI 1.26-4.34, P=0.007) and OS (HR=2.90, 95%CI 1.46-5.76, P=0.002) in the docetaxel-based group, but not in the non-docetaxel-based group. Restricted cubic splines revealed a “J-shaped” association of baseline BMI with risk of recurrence (P for non-linearity=0.111) or all-cause death (P for non-linearity=0.008), and this relationship was more pronounced in the docetaxel-based group (DFS: P for non-linearity=0.011; OS: P for non-linearity <0.001).

Conclusions

In early breast cancer patients treated with adjuvant chemotherapy, baseline severe obesity was lined to worse DFS and OS, while a BMI loss over 10% from baseline to post-adjuvant chemotherapy also negatively affected OS. Moreover, the prognostic role of BMI might differ between docetaxel-based and non-docetaxel-based groups.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.